Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Takahiko ItoAtsuo TakashimaKentaro YamazakiHiroki YukamiHiroyuki UetakeMasahiro TsudaTakeshi SutoToshikazu MoriwakiNaotoshi SugimotoHitoshi OjimaYasumasa TakiiHisateru YasuiTaito EsakiAkihito TsujiMasahiro GotoMasayuki SarutaSatoshi OtsuKatsunori ShinozakiToshiyoshi FujiwaraTakao TamuraEishi BabaManabu ShiozawaTadamichi DendaHideki UenoKengo NagashimaYasuhiro ShimadaPublished in: International journal of clinical oncology (2022)
Real-world data showed that OS was better with BEV than with CET/PAN in right-sided mCRC. However, there was no significant difference in OS in left-sided mCRC.